查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1618252

藥物釋放型血管支架:市場洞察·競爭環境·市場預測 (～2030年)

Drug-Eluting Stents - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

藥物釋放型支架市場規模預計將從 2023 年的 24 億美元成長到 2030 年的 37.8 億美元，預測期內複合年增長率為 7.88%。 藥物釋放型支架市場的主要推動因素是心血管疾病患者數量的增加，包括心房顫動、冠狀動脈疾病（CAD）和周邊動脈疾病（PAD）、創新產品開發工作以及微創技術的採用增加它見證了市場的顯著成長，預計這些因素將在2024 年至2030 年的預測期內推動整體市場成長。

藥物釋放型支架：市場動態

根據《世界心臟報告（2023）》提供的數據，2021年全球將有超過5億人罹患心血管疾病。此外，根據美國心臟協會（2023）最新提供的數據，預計到2030年，全球將有超過1,200萬人受到心房顫動的影響。

根據英國心臟基金會的全球心臟和循環系統疾病情況說明書（2024 年），全球約有 2 億人患有冠狀動脈疾病 (CAD)。

此外，根據美國心臟協會 (2023) 的數據，全球平均約有 2 億人患有周邊動脈疾病 (PAD)。此外，根據《全球疾病負擔》（2019 年），2019 年全球 40 歲至 70 歲的 PAD 患者人數估計為 5,640 萬人。

心血管疾病患者數量的增加顯著增加了對藥物釋放型支架的需求。隨著這些疾病在世界各地變得越來越普遍，對支架置入術等有效、微創治療的需求日益增長。支架技術的進步，以及心臟和循環系統疾病負擔的增加，使支架成為治療這些疾病的重要組成部分，在預防和治療保健策略中的作用越來越大。

就塗料而言，聚合物基塗料領域預計將在 2023 年佔據主要收入佔有率。這是由於藥物釋放型支架上聚合物基塗層的特性和應用不同所致。

應用於藥物釋放型支架的聚合物塗層可促進治療藥物的控制釋放，並且在預防冠狀動脈再狹窄方面非常有效。這些塗層旨在直接在支架部位逐漸、有針對性地釋放藥物，例如抗增殖和抗發炎藥物。這有助於抑制平滑肌細胞增生和新內膜增生，這是再狹窄的常見原因。此外，聚合物可以根據特定的親水或疏水特性進行定制，從而可以調整藥物釋放速率以優化治療效果。

按地區劃分，北美預計將佔據藥物釋放型支架市場的主要收入佔有率。這是由於多種因素造成的，包括大量患有 CAD、心肌梗塞和相關風險因素的患者、產品開發和監管審批方面的重大進展、領先公司的存在以及已建立的先進醫療基礎設施的可用性。

本報告提供全球藥物釋放型血管支架的市場調查，彙整市場概要，市場影響因素及市場機會分析，法律制度，市場規模的轉變·預測，各種區分·地區/各主要國家的詳細分析，競爭情形，主要企業簡介等資訊。

目錄

第1章 藥物釋放型血管支架市場報告:簡介

  • 調查範圍
  • 市場分類
  • 市場估計

第2章 藥物釋放型血管支架市場:摘要整理

  • 市場概要

第3章 競爭情形

第4章 法規分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第5章 藥物釋放型血管支架市場:主要要素分析

  • 推動市場要素
    • 慢性病發生率增加
    • 增加產品開發活動
    • 與生活方式相關的疾病增加
    • 對微創手術有興趣
  • 市場限制與課題
    • 與藥物洗脫支架相關的風險和併發症
    • 嚴格的監理審批流程
  • 市場機會
    • 生物可吸收血管支架的開發
    • 人工智慧與機器人整合進行支架置入

第6章 藥物釋放型血管支架市場:波特的五力分析

第7章 藥物釋放型血管支架市場評估

  • 各類型
    • 冠狀動脈支架拘留
    • 末梢支架置入
  • 支架類型
    • 白金鉻礦
    • 鈷鉻礦
    • 鎳鈦合金
    • 其他
  • 塗料
    • 聚合物為基礎的塗料
    • 聚合物自由塗料
  • 各藥物類型
    • Everolimus
    • Paclitaxel
  • 各終端用戶
    • 醫院
    • 門診病人手術中心
    • 專門診所
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區

第8章 藥物釋放型血管支架市場:企業·產品簡介

  • Medtronic
  • Abbott
  • Boston Scientific Corporation
  • B. Braun Melsungen AG
  • BIOTRONIK SE & Co. KG
  • Cook
  • Terumo Corporation
  • Lepu Medical Technology Co.,Ltd
  • Microport Scientific Corporation
  • Balton Sp.z.o.o
  • ENDOCOR GmbH
  • Eurocor Tech GmbH
  • Alvimedica
  • Biosensors International Group, Ltd.
  • Meril Life Sciences Pvt. Ltd.
  • Translumina
  • Sino Medical Sciences Technology Inc.
  • iVascular S.L.U
  • Sahajanand Laser Technology Limited
  • Cardionovum GmbH

第9章 KOL的見解

第10章 計劃的方法

第11章 關於DelveInsight

第12章 免責聲明·聯絡方式

Product Code: DIMDCL0231

Drug-Eluting Stents Market by Type (Coronary Stenting and Peripheral Stenting), Scaffold (Platinum-Chromium, Cobalt-Chromium, Nitinol, and Others), Coating (Polymer-based Coating [Biodegradable and Non-biodegradable] and Polymer-free Coating), Drug Type (Everomilus, Paclitaxel, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing cases of cardiovascular disorders and the rising product developmental activities worldwide

The drug-eluting stents market was valued at USD 2.40 billion in 2023, growing at a CAGR of 7.88% during the forecast period from 2024 to 2030 to reach USD 3.78 billion by 2030. The drug-eluting stents market is observing substantial market growth primarily owing to the increasing cases of cardiovascular disorders including atrial fibrillation and coronary artery disease (CAD), peripheral artery disease (PAD), innovative product developmental activities by regulatory bodies, and the rising adoption of minimally invasive techniques that are expected to escalate the overall growth of the drug-eluting stents market during the forecast period from 2024 to 2030.

Drug-Eluting Stents Market Dynamics:

As per data provided by the World Heart Report (2023), in 2021, it was stated that more than half a billion people were living with cardiovascular diseases globally. Further, according to recent data provided by the American Heart Association (2023), it is estimated that by 2030 over 12 million people will have atrial fibrillation globally.

According to British Heart Foundation, Global Heart & Circulatory Diseases Factsheet (2024), it stated that around 200 million people are living with coronary artery disease (CAD) around the world.

As per data by the American Heart Association (2023), around 200 million live with peripheral artery disease (PAD) globally on average. Also, as per the Global Burden of Disease (2019), there were 56.4 million prevalent cases of PAD among those aged 40 to 70, worldwide in 2019.

Thus, the rising instances of cardiovascular conditions are driving a significant increase in demand for drug-eluting stents. As these conditions become more widespread globally, the need for effective, minimally invasive treatments like stenting is growing. Advances in stent technology, along with the increasing burden of heart and circulatory diseases, are making stents a vital component in treating these conditions, enhancing their role in both preventive and therapeutic healthcare strategies.

Increased product developmental activities by regulatory bodies worldwide is also slated to drive the market growth for drug-eluting stents. For example, in May 2022, Medtronic announced that it received the U.S. Food and Drug Administration (FDA) approval for the Onyx Frontier(TM) drug-eluting stent (DES).

Hence, the interplay of all the above-mentioned factors is expected to drive the market for drug-eluting stents during the given forecast period from 2024 to 2030.

However, the risks and complications associated with drug-eluting stents, the stringent regulatory approval process, among others may prove to be challenging factors for the growth of the drug-eluting stents market.

Drug-Eluting Stents Market Segment Analysis:

Drug-Eluting Stents Market by Type (Coronary Stenting and Peripheral Stenting), Scaffold (Platinum-Chromium, Cobalt-Chromium, Nitinol, and Others), Coating (Polymer-based Coating [Biodegradable and Non-biodegradable] and Polymer-free Coating), Drug Type (Everomilus, Paclitaxel, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the coating segment of the drug-eluting stents market, the polymer-based coating category is expected to have a significant revenue share in 2023. This is due to the various features and applications of polymer-based coating of drug-eluting stents.

Polymer-based coatings on drug-eluting stents enhance the controlled release of therapeutic agents, making them highly effective in preventing restenosis in coronary arteries. These coatings are engineered to enable the gradual and targeted release of drugs, such as antiproliferative or anti-inflammatory agents, directly at the stent site. This helps in reducing smooth muscle cell proliferation and neointimal hyperplasia, which are common causes of restenosis. Additionally, polymers can be tailored for specific hydrophilicity and hydrophobicity, adjusting drug release rates to optimize therapeutic effects.

Applications of polymer-based coatings extend beyond coronary stents, as they are also used in peripheral artery disease, maintaining arterial patency in various vessels. Furthermore, these coatings can be combined with multiple drugs to address a broader range of complications, like restenosis and inflammation, providing versatile treatment options for different patient needs.

Therefore, the widespread uses of polymer-based coating, solidify the impact on the overall growth of the drug-eluting stents market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall drug-eluting stents market:

Among all the regions, North America is estimated to hold a significant revenue share in the drug-eluting stents market. This can be attributed to several factors including the high instances of CAD, myocardial infarction, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the drug-eluting stents market in the North America region during the forecast period from 2024 to 2030.

As per data provided by the National Institute of Health (2023), it stated that 20.5 million people in the US were living with CAD. Furthermore, according to data from the Centers for Disease Control and Prevention (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. Furthermore, as per the same source, it was stated that heart disease is an umbrella term that encompasses numerous indications such as acute coronary syndrome, atherosclerosis, and congestive heart failure among others. Some of the key risk factors associated with heart disease are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of Americans (47%) have at least one of these three risk factors.

According to data from the Canadian Institute for Health Information (2024), it stated that in 2022, 2.4 million Canadians were affected by heart disease.

Since cardiovascular disorders are rising in the region among middle-aged individuals, the demand for more effective diagnostic and treatment options is increasing significantly. This trend is fueling investment in innovative technologies and expanding the market for drug-eluting stents.

Product developmental activities initiated by regulatory bodies will further boost the market for drug-eluting stents. For example, in March 2024, Boston Scientific Corporation announced that it received U.S. Food and Drug Administration (FDA) approval for the AGENT(TM) Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.

The prompt and well-established healthcare services and infrastructure further contribute to the growth of the regional drug-eluting stents market growth. The presence of key players such as Abbott, Medtronic, and Boston Scientific Corporation with their strong distribution networks ensure widespread availability and accessibility of these devices across the region increasing their revenue shares in the market, and supportive reimbursement programs providing immense growth opportunities for the same.

Therefore, the interplay of all the factors mentioned above provides a conducive growth environment for the North America region in the drug-eluting stents market during the forecast period from 2024 to 2030.

Drug-Eluting Stents Market key players:

Some of the key market players operating in the drug-eluting stents market include Medtronic, Abbott, Boston Scientific Corporation, B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Cook, Terumo Corporation, Lepu Medical Technology Co., Ltd., Microport Scientific Corporation, Balton Sp.z.o.o, ENDOCOR GmbH, Eurocor Tech GmbH, Alvimedica, Biosensors International Group, Ltd., Meril Life Sciences Pvt. Ltd., Translumina, Sino Medical Sciences Technology Inc., iVascular S.L.U, Sahajanand Laser Technology Limited, Cardionovum GmbH, and others.

Recent Developmental Activities in the Drug-Eluting Stents Market:

  • In September 2021, Biotronik received regulatory approval from the US Food and Drug Administration for their Orsiro Mission bioabsorbable polymer drug-eluting stent system (BP-DES).
  • In June 2021, Abbott received product approval from the US FDA for their XIENCE family of stents for one-month (for 28 days) DAPT labeling for high bleeding risk (HBR) patients in the U.S.
  • In May 2021, Alvimedica received the CE mark approval for their NiTides self-expanding, drug-eluting stent, aimed for treating lesions associated with peripheral artery disease in the superficial femoral arteries.

Key takeaways from the Drug-Eluting Stents Market Report study

  • Market size analysis for current drug-eluting stents market size (2023), and market forecast for 6 years (2024 to 2030)
  • Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the drug-eluting stents market
  • Various opportunities available for other competitors in the drug-eluting stents market space
  • What are the top-performing segments in 2023? How these segments will perform in 2030?
  • Which are the top-performing regions and countries in the current drug-eluting stents market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for drug-eluting stents market growth in the coming future?

Target audience who can be benefited from this drug-eluting stents market report study

  • Drug-eluting stents providers
  • Research organizations and consulting companies
  • Drug-eluting stents related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in drug-eluting stents
  • Various end-users who want to know more about the drug-eluting stents market and the latest developments in the drug-eluting stents market

Frequently Asked Questions for the Drug-Eluting Stents Market:

1. What are drug-eluting stents?

  • The drug-eluting stent is a small mesh structure that is inserted into the artery to keep it open and also releases a medication that helps in preventing the formation of blood clots inside the stent.

2. What is the market for drug-eluting stents?

  • The drug-eluting stents market was valued at USD 2.40 billion in 2023, growing at a CAGR of 7.88% during the forecast period from 2024 to 2030 to reach USD 3.78 billion by 2030.

3. What are the drivers for the drug-eluting stents?

  • The drug-eluting stents market is observing substantial market growth primarily owing to the increasing cases of cardiovascular disorders including atrial fibrillation and coronary artery disease (CAD), peripheral artery disease (PAD), innovative product developmental activities by regulatory bodies, and the rising adoption of minimally invasive techniques that are expected to escalate the overall growth of the drug-eluting stents market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the drug-eluting stents?

  • Some of the major market players operating in the drug-eluting stents market include Medtronic, Abbott, Boston Scientific Corporation, B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Cook, Terumo Corporation, Lepu Medical Technology Co.,Ltd., Microport Scientific Corporation, Balton Sp.z.o.o, ENDOCOR GmbH, Eurocor Tech GmbH, Alvimedica, Biosensors International Group, Ltd., Meril Life Sciences Pvt. Ltd., Translumina, Sino Medical Sciences Technology Inc., iVascular S.L.U, Sahajanand Laser Technology Limited, Cardionovum GmbH, and others.

5. Which region has the highest share in the drug-eluting stents?

  • Among all the regions, North America is estimated to hold a significant revenue share in the drug-eluting stents market. This can be attributed to several factors including the high instances of CAD, myocardial infarction, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the drug-eluting stents market in the North America region during the forecast period from 2024 to 2030.

Table of Contents

1. Drug-Eluting Stents Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Drug-Eluting Stents Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Drug-Eluting Stents Market Key Factors Analysis

  • 5.1. Drug-Eluting Stents Market Drivers
    • 5.1.1. Increasing incidence of chronic disorders
    • 5.1.2. Rising product developmental activities
    • 5.1.3. Growing instances of life-style related disorders
    • 5.1.4. Increasing preference for minimally invasive procedures
  • 5.2. Drug-Eluting Stents Market Restraints and Challenges
    • 5.2.1. Risk and complications associated with drug-eluting stents
    • 5.2.2. Stringent regulatory approval process
  • 5.3. Drug-Eluting Stents Market Opportunities
    • 5.3.1. Development of bioresorbable vascular scaffolds
    • 5.3.2. Integrating AI and robotics for stent placement

6. Drug-Eluting Stents Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Drug-Eluting Stents Market Assessment

  • 7.1. By Type
    • 7.1.1. Coronary Stenting
    • 7.1.2. Peripheral Stenting
  • 7.2. By Scaffold
    • 7.2.1. Platinum-Chromium
    • 7.2.2. Cobalt-Chromium
    • 7.2.3. Nitinol
    • 7.2.4. Others
  • 7.3. By Coating
    • 7.3.1. Polymer-based Coating
      • 7.3.1.1. Biodegradable
      • 7.3.1.2. Non-Biodegradable
    • 7.3.2. Polymer-Free Coating
  • 7.4. By Drug Type
    • 7.4.1. Everolimus
    • 7.4.2. Paclitaxel
    • 7.4.3. Others
  • 7.5. By End-User
    • 7.5.1. Hospitals
    • 7.5.2. Ambulatory Surgical Centers
    • 7.5.3. Specialty Clinics
  • 7.6. By Geography
    • 7.6.1. North America
      • 7.6.1.1. United States Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.1.2. Canada Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.1.3. Mexico Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.2. Europe
      • 7.6.2.1. France Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.2.2. Germany Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.2.3. United Kingdom Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.2.4. Italy Drug-Eluting Stents market size in USD million (2021-2030)
      • 7.6.2.5. Spain Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.2.6. Rest of Europe Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.3. Asia-Pacific
      • 7.6.3.1. China Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.3.2. Japan Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.3.3. India Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.3.4. Australia Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.3.5. South Korea Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.3.6. Rest of Asia-Pacific Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.4. Rest of the World (RoW)
      • 7.6.4.1. Middle East Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.4.2. Africa Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.4.3. South America Drug-Eluting Stents Market Size in USD million (2021-2030)

8. Drug-Eluting Stents Market Company and Product Profiles

  • 8.1. Medtronic
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Abbott
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Boston Scientific Corporation
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. B. Braun Melsungen AG
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. BIOTRONIK SE & Co. KG
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Cook
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Terumo Corporation
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Lepu Medical Technology Co.,Ltd
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Microport Scientific Corporation
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Balton Sp.z.o.o
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. ENDOCOR GmbH
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Eurocor Tech GmbH
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Alvimedica
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Biosensors International Group, Ltd.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Meril Life Sciences Pvt. Ltd.
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Translumina
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Sino Medical Sciences Technology Inc.
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. iVascular S.L.U
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Sahajanand Laser Technology Limited
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Cardionovum GmbH
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Drug-Eluting Stents Market in Global (2021-2030)
  • Table 3: Drug-Eluting Stents Market in Global by Type (2021-2030)
  • Table 4: Drug-Eluting Stents Market in Global by Scaffold (2021-2030)
  • Table 5: Drug-Eluting Stents Market in Global by Coating (2021-2030)
  • Table 6: Drug-Eluting Stents Market in Global by Drug Type (2021-2030)
  • Table 7: Drug-Eluting Stents Market in Global by End-User (2021-2030)
  • Table 8: Drug-Eluting Stents Market in Global by Geography (2021-2030)
  • Table 9: Drug-Eluting Stents Market in North America (2021-2030)
  • Table 10: Drug-Eluting Stents Market in the United States (2021-2030)
  • Table 11: Drug-Eluting Stents Market in Canada (2021-2030)
  • Table 12: Drug-Eluting Stents Market in Mexico (2021-2030)
  • Table 13: Drug-Eluting Stents Market in Europe (2021-2030)
  • Table 14: Drug-Eluting Stents Market in France (2021-2030)
  • Table 15: Drug-Eluting Stents Market in Germany (2021-2030)
  • Table 16: Drug-Eluting Stents Market in United Kingdom (2021-2030)
  • Table 17: Drug-Eluting Stents Market in Italy (2021-2030)
  • Table 18: Drug-Eluting Stents Market in Spain (2021-2030)
  • Table 19: Drug-Eluting Stents Market in the Rest of Europe (2021-2030)
  • Table 20: Drug-Eluting Stents Market in Asia-Pacific (2021-2030)
  • Table 21: Drug-Eluting Stents Market in China (2021-2030)
  • Table 22: Drug-Eluting Stents Market in Japan (2021-2030)
  • Table 23: Drug-Eluting Stents Market in India (2021-2030)
  • Table 24: Drug-Eluting Stents Market in Australia (2021-2030)
  • Table 25: Drug-Eluting Stents Market in South Korea (2021-2030)
  • Table 26: Drug-Eluting Stents Market in Rest of Asia-Pacific (2021-2030)
  • Table 27: Drug-Eluting Stents Market in the Rest of the World (2021-2030)
  • Table 28: Drug-Eluting Stents Market in the Middle East (2021-2030)
  • Table 29: Drug-Eluting Stents Market in Africa (2021-2030)
  • Table 30: Drug-Eluting Stents Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Drug-Eluting Stents Market in Global (2021-2030)
  • Figure 3: Drug-Eluting Stents Market in Global by Type (2021-2030)
  • Figure 4: Drug-Eluting Stents Market in Global by Scaffold (2021-2030)
  • Figure 5: Drug-Eluting Stents Market in Global by Coating (2021-2030)
  • Figure 6: Drug-Eluting Stents Market in Global by Drug Type (2021-2030)
  • Figure 7: Drug-Eluting Stents Market in Global by End-User (2021-2030)
  • Figure 8: Drug-Eluting Stents Market in Global by Geography (2021-2030)
  • Figure 9: Drug-Eluting Stents Market in North America (2021-2030)
  • Figure 10: Drug-Eluting Stents Market in the United States (2021-2030)
  • Figure 11: Drug-Eluting Stents Market in Canada (2021-2030)
  • Figure 12: Drug-Eluting Stents Market in Mexico (2021-2030)
  • Figure 13: Drug-Eluting Stents Market in Europe (2021-2030)
  • Figure 14: Drug-Eluting Stents Market in France (2021-2030)
  • Figure 15: Drug-Eluting Stents Market in Germany (2021-2030)
  • Figure 16: Drug-Eluting Stents Market in United Kingdom (2021-2030)
  • Figure 17: Drug-Eluting Stents Market in Italy (2021-2030)
  • Figure 18: Drug-Eluting Stents Market in Spain (2021-2030)
  • Figure 19: Drug-Eluting Stents Market in the Rest of Europe (2021-2030)
  • Figure 20: Drug-Eluting Stents Market in Asia-Pacific (2021-2030)
  • Figure 21: Drug-Eluting Stents Market in China (2021-2030)
  • Figure 22: Drug-Eluting Stents Market in Japan (2021-2030)
  • Figure 23: Drug-Eluting Stents Market in India (2021-2030)
  • Figure 24: Drug-Eluting Stents Market in Australia (2021-2030)
  • Figure 25: Drug-Eluting Stents Market in South Korea (2021-2030)
  • Figure 26: Drug-Eluting Stents Market in Rest of Asia-Pacific (2021-2030)
  • Figure 27: Drug-Eluting Stents Market in the Rest of the World (2021-2030)
  • Figure 28: Drug-Eluting Stents Market in the Middle East (2021-2030)
  • Figure 29: Drug-Eluting Stents Market in Africa (2021-2030)
  • Figure 30: Drug-Eluting Stents Market in South America (2021-2030)
  • Figure 31: Market Drivers
  • Figure 32: Market Barriers
  • Figure 33: Marker Opportunities
  • Figure 34: PORTER'S Five Force Analysis